New Directions on WHO ARV Guidelines 2018
|
|
- Jacob Bruce
- 5 years ago
- Views:
Transcription
1 New Directions on WHO ARV Guidelines 2018 Elaine Abrams Co-chair WHO Guidelines Development Group ICAP at Columbia University, New York Martina Penazzato Paediatric lead for the HIV Department World Health Organization, Geneva
2 2016 WHO recommandations for 1st Line ART in Adults and Adolescents In 2017 WHO Recommendations: 1) Countries with national pretreatment HIVDR to EFV or NVP 10% should consider a RAPID transition to non-nnrti for all new ART starters 2) ART starters with reported prior exposure to ARVs: start a non-nnrti (i.e. DTG), regardless of level of PDR WHO Consolidated ARV Guidelines, 2016
3 PICO questions considered for the 2018 update 1. Should DTG (RAL for age groups where DTG is not approved) be recommended as the preferred first-line antiretroviral agent in combination with an age appropriate NRTI backbone for the treatment of HIV? 2. Should DTG (RAL for age groups where DTG is not approved) be recommended as the preferred second-line antiretroviral agent in combination with an age appropriate NRTI backbone for the treatment of HIV? 3. Should DTG (RAL for age groups where DTG is not approved) be antiretroviral agent in combination with an age appropriate NRTI backbone for HIV post-exposure prophylaxis (PEP)? 4. Should an indeterminate range be implemented for more accurate molecular diagnosis of infants under 18 months of age?
4 Safety and Efficacy of DTG and EFV600 in 1 st line ART (summary 2018 WHO Sys Review & NMA) Major Outcomes DTG vs EFV 600 Quality of Evidence Viral suppression (96 weeks) DTG better moderate Treatment discontinuation DTG better high CD4 recovery (96 weeks) DTG better moderate Mortality comparable low AIDS progression comparable low SAE comparable low Reference: Steve Kanters, For WHO ARV GDG, May 2018
5 New Findings informed the safety profile in women of child bearing potential NIH funded study has identified a potential safety issue and reported it to the World Health Organization (WHO) and ViiV Healthcare. Observational study in Botswana, which has found 4 cases of neural tube defects out of 426 women who became pregnant while taking DTG. This rate of approximately 0.9% compares to a 0.1% risk of neural tube defects in infants born to women taking other antiretroviral medicines at the time of conception. See presentation from Rebecca Zash et al tomorrow
6 Direction of the recommendations Available clinical evidence as well as assessment of the risk and benefits support the use of DTG as a preferred 3 rd agent in all lines of antiretroviral treatment and post-exposure prophylaxis in adults and adolescents, including women and adolescents girls using consistent and reliable contraception. Concerns around the safety of DTG use during periconception period were acknowledged resulting in specific qualifications on the use of DTG in women and adolescents girls of childbearing potential
7 Note of caution for using DTG in women and adolescent girls of childbearing potential Exposure to DTG at the time of conception may be associated with NTD risk among infants. DTG appears to be safe when started after the period of risk of neural tube defects (ie, up to 8 weeks after conception). Adolescent girls and women of childbearing potential who do not currently want to become pregnant can receive DTG together with consistent contraception (hormonal contraception and DTG have no reported or expected drug drug interactions). An EFV-based regimen is a safe and effective first-line regimen and can be used among women of childbearing potential during the period of potential risk for developing NTDs. National programmes should consider the balance of benefits and risks when selecting the optimal ARV regimen for women and adolescent girls of childbearing potential (fertility levels, contraceptive availability and coverage, pre-treatment NNRTI resistance, drug availability, maternal and infant toxicity profile).
8 Implementation considerations for adolescents DTG is of particular benefit to adolescents (sub-optimal adherence, EFV side-effects, triple class failure). In LMIC, half of the estimated 23 million pregnancies in adolescent girls (2 million in below 15 years) were unintended. Policy decisions on DTG are an opportunity to review access SRHR services and current status of their integration with HIV services. Ensuring that adolescent girls living with HIV are well informed of their options to prevent unintended pregnancies, and provided with pre-pregnancy care to avoid use of DTG during preconception. A differentiated approach for integrated adolescent-friendly services is needed together with direct involvement of adolescents.
9 Focus on Infants and children
10 Background 1.8 million children were estimated to live with HIV in 2017 In 2017, only 51 % of HIV-exposed infants received EID (by 2 mo) Increasing exposure to maternal ARVs offers new challenges to ensure accurate EID Treatment coverage remains poor with only 52% receiving ART Almost half of those on ART continue to receive NVP based regimens HIVDR to NNRTI is as high as 60% as demonstrated by multiple national surveys Virological suppression remains poor particularly in younger children Lack of potent, tolerable ARVs in age appropriate formulations remains a critical barrier to scale up of paediatric treatment globally Introduction of new ARVs can happen when proven to be effective in adult population as soon as safety and PK are available to inform dosing.
11 Considerations for use of DTG Extrapolation from adult efficacy data 1 Safety and PK from P and ODYSSEY 3 Some limited experience in clinical practice from CHIPS cohort 4 High genetic barrier integrase inhibitor Acceptability of once daily administration Feasibility in the context of simplified dosing Need for clarity on dosing during TB cotreatment Approved dosing below 15 kg to become available in late 2019 Need for strengthening of toxicity monitoring alongside introduction References: 1. Kanters et al 2018; 2. Viani et al 2015, Wiznia et al 2016, Ruel et al 2017; 3. Turkova et al 2018; 4 Collins et al 2018; 5. Archary
12 Considerations for use of RAL Extrapolation from adult efficacy data 1 Safety and PK from birth based on P1066 trial 2 Dosing for TB cotreatment available from P1101 trial 3 Limited experience with use in first line for young children 4 Low genetic barrier compared to DTG with potential selection of INSTI resistance (BD DTG following use of RAL) Feasibility and acceptability of granules 5 Recommendation for use of time-limited provision while possible is not desirable for procurement and supply 6 Need to provide a non NNRTI alternative for neonates and for settings where LPVr pellets might not be available References: 1. Kanters et al 2018; 2. Nachman et al 2014, Clarke et al. 2017; 3. Meyers et al 2018; 4. Personal communication IeDea/CIPHER; 5. Archary et al 2018; 6. APWG 2018.
13 Overall messages Move away from NNRTI-based regimens Introduce DTG as soon as possible Use the most potent non-nnrti option
14 Direction of the recommendations for 1st line NEONATES CHILDREN Preferred AZT+3TC+RAL 1 ABC+3TC+DTG 2 Alternatives Special circumstances 4 AZT+3TC+NVP AZT+3TC+LPV/r ABC+3TC+LPV/r ABC+3TC+RAL 2 ABC (or AZT)+3TC+EFV 3 ABC (or AZT)+3TC+RAL AZT+3TC+LPV/r AZT+3TC+RAL AZT+3TC+NVP 1 For the shortest time possible, until a solid formulation of LPV/r or DTG can be used 2 For age and weight groups with DTG approved dosing and where LPV/r is not available 3 In cases where no other alternatives are available 4 From 3 years of age
15 Direction of the recommendation for 2 nd and 3 rd line Population 1 st line 2 nd line 3 rd line Children 2 NRTI + LPV/r 2 NRTIs + DTG** 2 NRTIs + EFV 2 NRTIs + DTG*** 2 NRTI + DTG 2 NRTIs + (ATV/r or LPV/r) DRV/r + DTG**** ± 1-2 NRTIs Where possible consider optimization using genotyping * Optimized NRTI backbone should be used: AZT following TDF or ABC failure, and viceversa. **This applies to children for whom approved DTG dosing is available. RAL should remain the preferred 2 nd line for those children for whom approved DTG is not available ***This applies to children for whom approved DTG dosing is available. ATV/r or LPV/r should remain the preferred 2nd line for those children for whom approved DTG is not available. ****DTG based 3rd line following use of INSTI must be administered with DTG BD.
16 Support for implementation Guiding product selection in line with Global Guidelines Supporting transition to optimal regimens Soon available online at
17 PICO questions considered for the 2018 update 1. Should DTG (RAL for age groups where DTG is not approved) be recommended as the preferred first-line antiretroviral agent in combination with an age appropriate NRTI backbone for the treatment of HIV? 2. Should DTG (RAL for age groups where DTG is not approved) be recommended as the preferred second-line antiretroviral agent in combination with an age appropriate NRTI backbone for the treatment of HIV? 3. Should DTG (RAL for age groups where DTG is not approved) be antiretroviral agent in combination with an age appropriate NRTI backbone for HIV post-exposure prophylaxis (PEP)? 4. Should an indeterminate range be implemented for more accurate molecular diagnosis of infants under 18 months of age?
18 As MTCT rate decreases, so does the confidence on a positive EID result (positive predictive value) 20% MTCT 5% MTCT x 400 x 1,900 10% MTCT 1% MTCT True positive False positive True negative x 900 x 9,900
19 Several EID technologies exist Qualitative technologies generally report detected or not detected, which is interpreted as positive or negative, respectively. HOWEVER Low levels of viremia may not be due to infection but rather contamination at the point of collection or at the lab. THEREFORE An indeterminate range could minimize unnecessary All tests with WHO-PQ have high sensitivity > 98% treatment by having the sample repeat tested before treatment initiation.
20 Join us on AIDS 2018
21 Acknowledgements Treatment and Care team (WHO) Meg Doherty Nathan Ford Marco Vitoria Lara Vojnov Silvia Bertagnolio Chantal Migone Ajay Rangaraj Anisa Ghadrshenas Serena Brusamento Wole Ameyan Vindi Singh Systematic reviewers Guidelines Development Group members External Review Committee
22 The AIDS Free Working Group Is pleased to announce the launch of a new AIDS FREE TOOLKIT FOR THE ACCELERATION OF TESTING AND TREATMENT SCALE-UP IN CHILDREN AND ADOLESCENTS LIVING WITH HIV Coming soon at:
23 Toolkit for research and development of paediatric antiretroviral drugs and formulations In collaboration with experts from the Paediatric Antiretroviral Working Group Soon available at
Existing and most needed paediatric ARV formulations
Existing and most needed paediatric ARV formulations Martina Penazzato Paediatric HIV advisor WHO HIV Department, Geneva Mach 7th 2016 Paediatric coverage still lags behind 45 40 35 30 25 20 15 10 5 0
More informationCADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs
CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ Outline What s new in ARV Guidelines Drug optimisation
More informationOverview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014
AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING Overview of 2013 WHO consolidated ARV guidelines and update plans Marco Vitoria HIV/AIDS Department WHO Geneva September 2014 AMDS ANNUAL STAKEHOLDERS AND
More informationAchieving the 3 rd 90 in PEPFAR-supported countries:
Center for Global Health Achieving the 3 rd 90 in PEPFAR-supported countries: What will it take? Is it enough? Elliot Raizes, MD Division of Global HIV and TB Centers for Disease Control and Prevention
More informationHIV TREATMENT INTERIM
POLICY BRIEF UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV JULY 2018 HIV TREATMENT INTERIM
More informationUPDATE ON ANTIRETROVIRAL REGIMENS FOR TREATING AND PREVENTING HIV INFECTION AND UPDATE ON EARLY INFANT DIAGNOSIS OF HIV
POLICY BRIEF UPDATE ON ANTIRETROVIRAL REGIMENS FOR TREATING AND PREVENTING HIV INFECTION AND UPDATE ON EARLY INFANT DIAGNOSIS OF HIV JULY 2018 HIV TREATMENT INTERIM GUIDANCE WHO/SEARO Gary Hampton WHO/CDS/HIV/18.19
More information2009 Revisions of WHO ART Guidelines. November 2009
2009 Revisions of WHO ART Guidelines November 2009 Guidelines Development Process 01/09 2009 WHO ART guideline revision process Scope of the work 03/09 WHO Guideline review committee approval 04/09 05/09
More informationTreatment Optimisation Community Condultation Feedback. KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016
Treatment Optimisation Community Condultation Feedback KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016 INTRODUCTION A brief history of ART 1987-90s AZT vecomes available ddi/ddc
More informationUpdate on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines
WHO 2013 Consolidated ARV Guidelines Update on global guidelines H I V / A I D S DEPARTMENT and emerging issues on perinatal HIV prevention Children & HIV, St. Petersburg, Russia Sept 25-26, 2014 Dr. Nathan
More informationARV Consolidated Guidelines 2015
ARV Consolidated Guidelines 2015 This document outlines the draft list of PICO questions to support systematic review process for the 2015 ARV guidelines process. PICO questions are grouped by clinical
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationReview of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA
Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo MMed
More informationUpdate on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges
Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato,
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More informationDEPARTMENT. Treatment Recommendations for. Pregnant and Breastfeeding Women: Critical Issues Consolidated ARV Guidelines. Dr.
2013 Consolidated ARV Guidelines H I V / A I D S Treatment Recommendations for DEPARTMENT Pregnant and Breastfeeding Women: Critical Issues Dr. Nathan Shaffer Objectives of Presentation obackground ooverview
More informationOptimizing Paediatric and Adolescent ART: Challenges and Opportunities
Optimizing Paediatric and Adolescent ART: Challenges and Opportunities Dr Nandita Sugandhi ICAP at Columbia University PATA 2017 Continental Summit 24 October, 2017 Johannesburg South Africa Overview What
More informationUpdate on the IATT Paediatric Formulary. WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland
Update on the IATT Paediatric Formulary WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland Summary The Challenge Rationale for Paediatric ARV Formulary Optimization 2015 Revised
More informationConsiderations for the Introduction of TLD in National Programs: PEPFAR Guidance on Developing Clinical and Programmatic Recommendations
Considerations for the Introduction of TLD in National Programs: PEPFAR Guidance on Developing Clinical and Programmatic Recommendations December 2018 2 Table of Contents ACRONYMS... 3 INTRODUCTION...
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationMedical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum
Medical Challenges of HIV/AIDS pandemic: The WHO perspective SOLTHIS HIV Forum Marco Vitoria HIV/AIDS Department World Health Organization September 2013 Topic 2002 2003 2006 2010 2013 When to start 1
More informationUNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE
UNICEF/Malawi/2015/Schermbrucker policy brief IATT PAEDIATRIC ARV FORMULARY AND LIMITED-USE LIST: 2016 UPDATE BACKGROUND Delivery of antiretroviral treatment (ART) to children living with HIV is associated
More informationAdvancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new
Advancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new H I V / A I D S D e p a r t m e n t WHO HQ Meg Doherty, MD, MPH, PhD Coordinator Treatment and Care November 5, 2012 1 Overview
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationIATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationWorld Health Organization Strategy for HIV Drug Resistance Surveillance in Low- and Middle- Income Countries
World Health Organization Strategy for HIV Drug Resistance Surveillance in Low- and Middle- Income Countries Silvia Bertagnolio, MD World Health Organization, Geneva Lusaka, 6 May 2014 Key characteristics
More informationEmerging Issues in HIV and Pregnancy. Lynne M. Mofenson, MD. HIV Senior Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation
Emerging Issues in HIV and Pregnancy Lynne M. Mofenson, MD HIV Senior Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation Perinatal Transmission in the ART Era What s New? Antepartum ARV drug
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationRationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi
Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi Presented by: Nandita Sugandhi M.D. 6 th International Workshop on HIV Pediatrics July
More informationHIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
More informationTunisian recommendations on ART : process and results
Second Arab Congress of Clinical Microbiology and Infectious Diseases May 24-26, 2012. Tunisian recommendations on ART : process and results M. BEN MAMOU UNAIDS Email: BenmamouM@unaids.org M. CHAKROUN
More informationPaediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme [2].tiff
Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme- 20171031[2].tiff Mo Archary King Edward VIII Hospital / UKZN Paediatric Infectious Diseases Unit Overview State
More informationChallenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs. Presented by Shaffiq Essajee (CHAI, USA)
Challenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs Presented by Shaffiq Essajee (CHAI, USA) Optimize paediatric ARVs and shape the market PADO New drugs,
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationCONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION WHAT S NEW
POLICY BRIEF CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION WHAT S NEW NOVEMBER 2015 WHO Library Cataloguing-in-Publication Data Policy brief: consolidated
More informationHistoric Perspective on HIV and TB Research in Pregnant Women
Historic Perspective on HIV and TB Research in Pregnant Women Lynne M. Mofenson, M.D. Senior HIV Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation High Burden of TB/HIV in Women - 2016 TB HIV
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationART Optimization (New emerging molecules) KPA PRE-CONFERENCE 24 th April 2018 Dr Justine Jelagat Odionyi (EGPAF)/Dr Virginia Karanja(CHS)
ART Optimization (New emerging molecules) KPA PRE-CONFERENCE 24 th April 2018 Dr Justine Jelagat Odionyi (EGPAF)/Dr Virginia Karanja(CHS) Outline Introduction New ART molecules already adopted Dolutegravir
More informationHIV und AIDS- was gibt es Neues für die Arbeit vor Ort?
HIV und AIDS- was gibt es Neues für die Arbeit vor Ort? Dr. med. Ralf Weigel Liverpool School of Tropical Medicine ralf.weigel@lstmed.ac.uk foring UPDATE 2017 Humanitäre Hilfe und Entwicklungszusammenarbeit
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More informationPatient Forecasts for Pipeline ARVs: Adults
Patient Forecasts for Pipeline ARVs: Adults Presented at: WHO/UNAIDS Annual Meeting with ARV Manufacturers and Stakeholders March 19-20, 2015 Vineet Prabhu Market Intelligence Team, CHAI HIV Access Program
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationUPDATE ON THE CLINICAL MANAGEMENT OF HIV IN BARBADOS
UPDATE ON THE CLINICAL MANAGEMENT OF HIV IN BARBADOS 82 nd UWI/ BAMP CME November 18th and 19th, 2017 Tiffany Jordan, MB BS Locum Clinical Medical Officer, Ladymeade Reference Unit OBJECTIVES 1. Epidemiology
More informationCan we make first line ART better?
Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationApplication for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children
Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children Table of Contents 1. Summary statement of proposal for inclusion...
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationMANAGING HIV IN CHILDREN: BEST PRACTICES
MANAGING HIV IN CHILDREN: BEST PRACTICES Dr. Mo Archary Paediatric Infectious Diseases Specialist University of KwaZulu Natal/ King Edward VIII Hospital Overview Global state of paediatric ART Filling
More informationNew Directions in the 2015 Consolidated ARV Guidelines Update. Meg Doherty, MD, PhD, MPH 19 July 2015 WHO Satellite Vancouver IAS 2015
New Directions in the 2015 Consolidated ARV Guidelines Update Meg Doherty, MD, PhD, MPH 19 July 2015 WHO Satellite Vancouver IAS 2015 Objectives of Presentation 2015 ARV Guidelines update - why now? Overview
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationImmediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)
Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts) Roselyne TOBY,MD, ID specialist Infectious Disease Unit/Yaounde Central Hospital
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationHIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
More informationART TREATMENT PROGRAMME 2004
Presentation title ART TREATMENT PROGRAMME 2004 Cabinet decision in 29 th November 2003 Initial sites were hospital based, required central review National Costing Model of HIV/AIDS Treatment 2010 Cost
More informationThe New National Guidelines. Feeding in the Context of HIV. Dr. Godfrey Esiru; National PMTCT Coordinator
The New National Guidelines (2010) for PMTCT and Infant Feeding in the Context of HIV Dr. Godfrey Esiru; National PMTCT Coordinator Presentation outline Evolution of the PMTCT guidelines in Uganda Rational
More informationTOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV
TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV Gladwel Muthoni KPA Conference 24 th April, 2018 OUTLINE Burden of HIV in PMTCT Mechanism and timing of Mother to Child Transmission (MTCT) Four
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationWEB ANNEX B. SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS ASSESSING FIRST-LINE ART TREATMENTS
WEB ANNEX B. SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS ASSESSING FIRST-LINE ART TREATMENTS Steve Kanters, Jeroen Jansen, Michael Zoratti, Jamie Forrest, Brittany Humphries, Jonathon Campbell
More informationThe 2017 Namibia ART Guidelines. Tadesse T. Mekonen, MD, MPH, AAF-HIV
The 2017 Namibia ART Guidelines Tadesse T. Mekonen, MD, MPH, AAF-HIV Q1-Table 1 List at least four key new recommendations in the 2017 Namibian ART Guidelines Q2-Table-2 46yo, Male, on AZT/TDF/FTC/ATVr
More informationProgress toward Universal ART Access: Innovations and Treatment 2.0. Marco Vitoria World Health Organization September 2013
Progress toward Universal ART Access: Innovations and Treatment 2.0 Marco Vitoria World Health Organization September 2013 The need for scalable, more efficient treatment models Simpler drugs Point of
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationSupporting Sustained Supply through the Coordinated Procurement of ARVs
Supporting Sustained Supply through the Coordinated Procurement of ARVs ARV Procurement Working Group Newsletter April 2018 Introduction Through quarterly order cycles and business calls, the APWG has
More informationCan we make first line ART better?
Can we make first line ART better? Dr David Stead Treatment Optimization HIV Clinicians Society Workshop 25 November 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationUganda. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)
WHO/CDS/HIV/18.50 Demographic and socioeconomic data Uganda HIV Country Pro le: 2017 42.9 million Total population (2017) 1 820 US$ GNI per capita, PPP (2017) 343 Maternal mortality per 100 000 live births
More informationThe Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations
Slide 1 The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations Sébastien Morin (International AIDS Society, Switzerland) 9 th
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationINTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY
PHARMACOKINETIC AND 4-WEEK SAFETY/EFFICACY OF DOLUTEGRAVIR (S/GSK1349572) DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN AGED 4 WEEKS TO
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationThe CQUIN Learning Network
The CQUIN Learning Network Adolescents Living with HIV: National Guidelines, Minimum Package, Challenges and Priorities Swaziland Ms Nobuhle Mthethwa MOH- SWAZILAND October 24-27, 2017 Johannesburg, South
More informationMODERN ART FOR AFRICA
MODERN ART FOR AFRICA March 2018 A guide for HIV treatment activists and communities in lowand middle-income countries ART today A pricing agreement was recently announced that will speed up access to
More informationPretreatment drug resistance and new treatment paradigms in firstline
Michelle Moorhouse October 2018 27 th International Workshop on HIV Drug Resistance and Treatment Strategies Pretreatment drug resistance and new treatment paradigms in firstline ART Disclosures/disclaimers
More informationManagement of HIV Infected Children and Adolescents: Public Sector Approach in Kenya
Management of HIV Infected Children and Adolescents: Public Sector Approach in Kenya KPA 2018 24-04-2018 Dr. Margaret Wainaina- Wafula Outline Introduction Evaluation of a child living with HIV. Standard
More informationBotswana. HIV Country Profile: Health expenditure, total (% of GDP) (2016) Total fertility rate (births per woman) ( )
WHO/CDS/HIV/18.5 Demographic and socioeconomic data Botswana HIV Country Profile: 217 2.3 million Total population (217) 16 99 US$ GNI per capita, PPP (217) World Bank 129 Maternal mortality per 1 live
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationDECLINE IN POSITIVITY RATES AMONG HIV-EXPOSED INFANTS WITH CHANGES IN PMTCT ARV REGIMENS IN NIGERIA: EVIDENCE FROM 7 YEARS OF FIELD IMPLEMENTATION
Abst#_O_01 DECLINE IN POSITIVITY RATES AMONG HIV-EXPOSED INFANTS WITH CHANGES IN PMTCT ARV REGIMENS IN NIGERIA: EVIDENCE FROM 7 YEARS OF FIELD IMPLEMENTATION Hadiza Khamofu, 1 Edward Oladele, 1 Uche Ralph-Opara,
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationDr HM Sebitloane Chief Specialist (Outreach) Dept of O+G NRMSM
Dr HM Sebitloane Chief Specialist (Outreach) Dept of O+G NRMSM SA Background Population: 48m Annual number of deliveries:1,2m 97% of women attend the first ANC 71% of women attend 5 th ANC visit 97% of
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationImpact of ART resistance in sub Saharan Africa
Impact of ART resistance in sub Saharan Africa Elliot Raizes, MD Division of Global HIV/TB US Centers for Disease Control and Prevention ITREMA Resistance Training Workshop 24 October, 2018 Center for
More informationUsing new ARVs in pregnancy
Using new ARVs in pregnancy Linda-Gail Bekker With thanks to CN Mnyani SA HIV Clinician s Society Meeting 3 June 2017 We have effective drugs. There is no reason why any mother should die of AIDS. There
More informationObstetrics and HIV An Update. Jennifer Van Horn MD University of Utah
Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management
More informationClinical Pharmacology and Formulation Challenges of Pediatric Antiretroviral Treatment
Clinical Pharmacology and Formulation Challenges of Pediatric Antiretroviral Treatment Tim R. Cressey Research Associate PHPT-IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University,
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationCHAI Cambodia: HIV Program Update NCHADS Annual Operational Comprehensive Planning Workshop Dec 3, 2012
CHAI Cambodia: HIV Program Update NCHADS Annual Operational Comprehensive Planning Workshop Dec 3, 2012 1 CHAI areas of collaboration with NCHADS 1. HIV Program Context: Background 1. emtct 2. Drug Access
More informationCote D'Ivoire. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)
WHO/CDS/HIV/18.50 Demographic and socioeconomic data Cote D'Ivoire HIV Country Pro le: 2017 24.3 million Total population (2017) 3 820 US$ GNI per capita, PPP (2017) 645 Maternal mortality per 100 000
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationPaediatrics and adolescents
Paediatrics and adolescents SAMU SUMMARIES January 2018 samumsf.org Objectives of this Presentation To describe epidemiology the global response to HIV in both populations: children and adolescents To
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More information